- Home
- Technology & Engineering
- Civil
- Coagulation and Ultrafiltration in Seawater Reverse Osmosis Pretreatment
Coagulation and Ultrafiltration in Seawater Reverse Osmosis Pretreatment
- Availability: Confirm prior to ordering
- Branding: minimum 50 pieces (add’l costs below)
- Check Freight Rates (branded products only)
Branding Options (v), Availability & Lead Times
- 1-Color Imprint: $2.00 ea.
- Promo-Page Insert: $2.50 ea. (full-color printed, single-sided page)
- Belly-Band Wrap: $2.50 ea. (full-color printed)
- Set-Up Charge: $45 per decoration
- Availability: Product availability changes daily, so please confirm your quantity is available prior to placing an order.
- Branded Products: allow 10 business days from proof approval for production. Branding options may be limited or unavailable based on product design or cover artwork.
- Unbranded Products: allow 3-5 business days for shipping. All Unbranded items receive FREE ground shipping in the US. Inquire for international shipping.
- RETURNS/CANCELLATIONS: All orders, branded or unbranded, are NON-CANCELLABLE and NON-RETURNABLE once a purchase order has been received.
Product Details
Overview
This study investigates the role of coagulation in enhancing hydraulic performance and permeate quality of UF membranes and provides insight into options for minimizing or ideally eliminating coagulation from UF pre-treatment to SWRO. Results show that coagulation improves UF hydraulic performance mainly by reducing non-backwashable fouling of the membranes. This can be achieved at very low coagulant dose (~ 0.5 mg Fe/L) by coating the membranes with sub-micron particles.
Additionally, the work highlights the applicability of UF membranes with low molecular weight cut-off as the coagulant free future of SWRO pre-treatment. Major benefits in terms of reduced environmental impact is expected when applying membranes with low molecular weight cut-off, as the need for coagulation is eliminated while ensuring longevity of downstream SWRO membranes. In general terms, the research indicates that coagulant consumption can be significantly reduced in UF pre-treatment of SWRO by optimizing operational parameters and applying alternative solutions.








